Fused Or Hybrid Cells Patents (Class 435/70.2)
-
Publication number: 20100278875Abstract: The present invention provides PGE2 as a novel adjuvant for enhancing the immune response in a host, as well as methods of using PGE2 to enhance B cell response and thereby increasing antibody titer against a given immunogen are also disclosed and antibodies produced by at least one method of the present invention.Type: ApplicationFiled: September 28, 2007Publication date: November 4, 2010Inventors: Jill Giles-Komar, Michael A. Rycyzyn
-
Publication number: 20100278832Abstract: BST2 antibodies were selected by using as an indicator the binding between BST2 antibodies and various splicing variants of human BST2 antigen. As a result, the present inventors successfully obtained BST2 antibodies that specifically recognize BST2D, which has been reported to be expressed at high levels in cancer cells. The antibodies of the present invention specifically bind to cells expressing BST2D. Non-specific antibody binding to non-target tissues, which results in the decrease of antibody concentration in blood, can be prevented by using the antibodies of the present invention therapeutically. Alternatively, the present invention provides diagnostic agents comprising an antibody of the present invention, which specifically detect tissues expressing BST2D.Type: ApplicationFiled: October 16, 2008Publication date: November 4, 2010Inventors: Yumiko Kamogawa, Sahori Namiki, Minkwon Cho, Koji Ishida
-
Patent number: 7732168Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.Type: GrantFiled: August 21, 2008Date of Patent: June 8, 2010Assignee: Epitomics, IncInventors: Robert Pytela, Weimin Zhu, Yaohuang Ke, Qi Qian, Harry C. Au
-
Publication number: 20100068205Abstract: Antibodies specific for methionine sulfoxide residues on proteins are provided. The antibodies are prepared using methionine-rich zein proteins, which are oxidized, as antigens.Type: ApplicationFiled: October 6, 2009Publication date: March 18, 2010Inventor: Jackob Moskovitz
-
Patent number: 7655232Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.Type: GrantFiled: January 12, 2007Date of Patent: February 2, 2010Assignee: Pfizer Inc.Inventors: Jaume Pons, Arnon Rosenthal
-
Publication number: 20090317869Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.Type: ApplicationFiled: May 1, 2009Publication date: December 24, 2009Applicant: Seattle Genetics, Inc.Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
-
Patent number: 7598030Abstract: This disclosure relates to methods for selecting antibodies having desirable characteristics from a population of diverse antibodies. More specifically, this disclosure provides methods for identifying antibodies which bind to cancer cells, but which do not bind to human red or white blood cells or normal tissue cells. Antibodies of the disclosure can be used for therapeutic and/or diagnostic purposes.Type: GrantFiled: July 8, 2005Date of Patent: October 6, 2009Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Hong Xin, Toshiaki Maruyama, Naveen Dakappagari
-
Patent number: 7598351Abstract: The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand.Type: GrantFiled: December 3, 2004Date of Patent: October 6, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Hirokazu Matsumoto, Chieko Kitada, Shuji Hinuma
-
Patent number: 7592427Abstract: Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2R?; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response.Type: GrantFiled: November 28, 2006Date of Patent: September 22, 2009Assignee: ZymoGenetics, Inc.Inventors: Pallavur V. Sivakumar, Stephen R. Jaspers
-
Publication number: 20090221040Abstract: The present invention relates to an antibody active against a fusion polypeptide comprising a histidine portion, a process for the preparation thereof and its use.Type: ApplicationFiled: May 14, 2009Publication date: September 3, 2009Applicant: Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Hanswalter ZENTGRAF, Claudia TESSMER, Iris VELHAGEN, Susanne SCHWINN, Manfred FREY
-
Publication number: 20090203078Abstract: The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2/0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent.Type: ApplicationFiled: February 2, 2009Publication date: August 13, 2009Inventors: Tatsuya OGAWA, Yoshinobu Konno, Naohisa Akashi, Hiroshi Takasugi, Seiji Sugimoto, Keiichi Yano
-
Patent number: 7572895Abstract: The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the transferrin receptor, methods of diagnosing and treating various human cancers and diseases that express transferrin receptor.Type: GrantFiled: June 7, 2005Date of Patent: August 11, 2009Assignee: Raven Biotechnologies, Inc.Inventors: Jennie P. Mather, Penelope E. Roberts, Ronghao Li
-
Patent number: 7569364Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.Type: GrantFiled: April 11, 2005Date of Patent: August 4, 2009Assignee: Pfizer Inc.Inventors: Arnon Rosenthal, David L. Shelton, Patricia A. Walicke
-
Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs
Patent number: 7569676Abstract: The present invention comprises novel analogs of ecstasy-class compounds and novel ecstasy-class immunogens leashed out of, i.e., derived from, the methylenedioxy position. The invention also comprises unique monoclonal antibodies generated using MDO-leashed MDMA immunogens as well as unique conjugates and tracers. These antibodies, conjugates, and tracers are useful in immunoassays for the detection of ecstasy-class compounds in biological fluids.Type: GrantFiled: March 9, 2005Date of Patent: August 4, 2009Assignee: Roche Diagnostics Operations, Inc.Inventors: Mitali Ghoshal, Gerald F. Sigler, Richard Terry Root, Anlonga Ouyang, Salvatore J. Salamone -
Patent number: 7537761Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: GrantFiled: October 21, 2005Date of Patent: May 26, 2009Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret Dow Moore
-
Publication number: 20090110682Abstract: Disclosed is an antibody having a high inhibitor effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation can be provided.Type: ApplicationFiled: June 19, 2006Publication date: April 30, 2009Applicants: Medical & Biological Laboratories Co., Ltd., The President of National Center for Geriatrics and Gerontology, Katsuhiko Yanagisawa c/o National Center for Geriatrics and GerontologyInventors: Katsuhiko Yanagisawa, Masao Shibata
-
Patent number: 7524650Abstract: New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing them.Type: GrantFiled: March 31, 2004Date of Patent: April 28, 2009Assignees: INSERM, Biomerieux SAInventors: Marie-Anne Petit, Colette Jolivet-Reynaud
-
Patent number: 7507797Abstract: Single-chain antibodies are described which specifically recognize both the 37 kDa precursor form of the laminin receptor (37 kDa LRP) and the 67 kDa high-affinity form of the laminin receptor (67 kDa LR), and pharmaceutical and diagnostic compositions which contain these single-chain antibodies.Type: GrantFiled: October 8, 2004Date of Patent: March 24, 2009Assignee: Affimed Therapeutics AGInventors: Stefan Knackmuss, Clémence Rey, Peter Röttgen, Claudia Büttner, Uwe Reusch
-
Patent number: 7501264Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.Type: GrantFiled: August 17, 2007Date of Patent: March 10, 2009Assignee: Biogen Idec Inc.Inventors: Darrell R. Anderson, Nabil Hanna, Peter Brams
-
Publication number: 20080287348Abstract: The present invention relates to a soluble hybrid protein, comprising at least a first polypeptide sequence derived from a prion protein PrPc that is capable of binding a protein responsible for transmissible spongiform encephalitis (PrPSc), and a second polypeptide sequence (tag), wherein said hybrid protein does not comprise a functional membrane anchor moiety. Also, the present invention is directed to the use of said hybrid proteins for the diagnosis of transmissible spongiform encephalopathies. In addition, the present invention relates to the use of said hybrid protein, a nucleic acid encoding said hybrid protein, a vector, and/or a host cell comprising a nucleic acid encoding said hybrid protein for the preparation of a medicament for the prevention or treatment of transmissible spongiform encephalopathies (TSEs).Type: ApplicationFiled: March 12, 2004Publication date: November 20, 2008Applicant: University of ZuerichInventors: Adriano Aguzzi, Nicolas Genoud, Alex Raeber
-
Publication number: 20080274477Abstract: A 53 Kd novel form of factor XIIa and related products, including nucleic acid molecules, monoclonal and polyclonal antibodies and hybridoma cell lines. Also assays for a 53 Kd form of factor XIIa and uses of said assays in diagnostic and prognostic methods, for example in the prediction of survival following myocardial infarction.Type: ApplicationFiled: January 10, 2006Publication date: November 6, 2008Inventor: David John Pritchard
-
Patent number: 7442550Abstract: A method for detecting the expression of a polypeptide in cells and for detecting the interaction between a polypeptide and cells, ex vivo or in vitro, wherein the polypeptide is selected from the group consisting of: a peptide comprising the cyt domain of the envelope protein of the human endogenous retrovirus, HERV-W; a peptide comprising amino acids 448-538 of SEQ ID NO: 1; and a peptide comprising a sequence having, for any series of 20 amino acids, at least 80% identity with amino acids 448-538 of SEQ ID NO: 1. Detection is established by the fusogenic power of the polypeptide, which is demonstrated by syncytia formation.Type: GrantFiled: September 1, 2000Date of Patent: October 28, 2008Assignees: Biomerieux, Institut National de la Sante et de la Recherche MedicaleInventors: Francois Mallet, Francois-Loic Cosset, Jean-Luc Blond, Dimitri Lavillette, Olivier Bouton, Alessia Ruggieri
-
Patent number: 7435553Abstract: A method of detecting and isolating cells that produce any secreted protein of interest (POI), comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule.Type: GrantFiled: May 15, 2006Date of Patent: October 14, 2008Assignee: Regeneron Pharmaceuticals, Inc.Inventors: James P Fandl, Neil Stahl, Gang Chen, George D. Yancopoulos
-
Patent number: 7427669Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: December 13, 2006Date of Patent: September 23, 2008Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 7410771Abstract: A reagent and method for the specific and highly sensitive detection of C. parvum in which the reagent is an antibody for a soluble C. parvum sporozoite antigen and the method is an immunoassay in which the antibody is used to detect or quantify C. parvum sporozoite antigen in a sample. The sample is treated to cause excystation of C. parvum oocytes, thereby releasing a C. parvum sporozoite antigen, and combined with antibodies specific for the sporozoite antigen under conditions to form an antibody-antigen complex. Detection of the complex indicates the presence of C. parvum in the sample. The assay allows recognition and detection of C. parvum in turbid samples, and due to a lack of crossreactivity with other Cryptosporidium species, is specific for C. parvum contamination or infection. The assay is highly sensitive, allowing for the detection of less than 100 oocysts per milliliter of sample.Type: GrantFiled: April 14, 2006Date of Patent: August 12, 2008Assignee: The United States of America as represented by the Department of Health and Human Services, Center for Disease Control and PreventionInventors: Victor C. W. Tsang, Jeffrey L. Call, Yeuk-mui Lee, Kathy Hancock
-
Publication number: 20080145861Abstract: The present invention relates to cells that can be passaged in culture and can be used for, among other things, promoter assays and the production of heterologous proteins.Type: ApplicationFiled: February 1, 2008Publication date: June 19, 2008Inventors: Jeffrey C. Rapp, Stephen H. Parker, Markley C. Leavitt, Dawn M. Eberhardt, Leandro Christmann, Alex J. Harvey
-
Publication number: 20080131930Abstract: The invention relates to means and methods for regulating gene expression and production of proteinaceous molecules. The invention provides a method for producing a proteinaceous molecule in a cell comprising selecting a cell for its suitability for producing the proteinaceous molecule, providing a nucleic acid encoding the proteinaceous molecule with a nucleic acid comprising a STAR (STabilizing Anti-Repression) sequence, expressing the resulting nucleic acid in the cell and collecting the proteinaceous molecule. Providing at least one STAR sequence to a nucleic acid encoding a proteinaceous molecule will enhance production (yield) of the proteinaceous molecule by a host cell, increase the proportion of host cells with acceptable expression levels, and/or increase stability of a gene expression level.Type: ApplicationFiled: July 31, 2007Publication date: June 5, 2008Applicant: ChromaGenics B.V.Inventors: Arie P. Otte, Arthur L. Kruckeberg, David P.E. Satijn
-
Patent number: 7342105Abstract: The antibody of the present invention, which specifically reacts with the N-terminal or C-terminal partial peptide of TGR23-2 ligand, is useful in detecting and quantifying the TGR23-2 ligand. Moreover, it is useful as a preventing/treating agent and a diagnostic agent for cancer, etc.Type: GrantFiled: February 26, 2004Date of Patent: March 11, 2008Assignee: Takeda Chemcial Industries, Ltd.Inventors: Hirokazu Matsumoto, Eri Hashimoto, Masaaki Mori, Chieko Kitada
-
Patent number: 7220559Abstract: This invention provides: a heteromyeloma, other than B6B11, capable of producing a trioma when fused with a human lymphoid cell, wherein the trioma is capable of producing a monoclonal antibody-secreting tetroma when fused with a second, antibody-secreting human lymphoid cell; a trioma fusion partner which does not produce antibody, obtained by fusing a heteromyeloma which does not produce antibody with a human lymphoid cell; a monoclonal antibody-secreting tetroma, obtained by fusing a trioma which does not produce antibody with an antibody-secreting human lymphoid cell; a method of producing a monoclonal antibody that specifically recognizes an antigen associated with a condition; a method of identifying an antigen associated with a condition using the trioma fusion partner; a method of diagnosing a condition using the trioma fusion partner; a method for preventing a condition; and compositions and therapeutic compositions comprising monoclonal antibodies produced using the trioma fusion partner.Type: GrantFiled: January 23, 2001Date of Patent: May 22, 2007Assignee: The Trustees of Columbia University in the City of New YorkInventor: Ilya Trakht
-
Patent number: 7196175Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.Type: GrantFiled: November 7, 2003Date of Patent: March 27, 2007Assignee: Japan Tobacco Inc.Inventors: Takuya Tamatani, Katsunari Tezuka
-
Patent number: 7193058Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: June 23, 2004Date of Patent: March 20, 2007Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 7169577Abstract: The present invention provides methods and devices for screening a single cell or a small group of cells for a desired biological activity. In particular, the present invention provides for delivering cell(s) to a plurality of cell isolation regions of a cell isolation device, transferring cell(s) to a plurality of wells of a cell expansion device and then detecting the potential desired biological activity of the cell(s). Each of the receptacles comprise a recess sized to isolate a single cell or small group of cells and each of the wells encompass a cavity that provides sufficient volume for cell proliferation.Type: GrantFiled: July 29, 2002Date of Patent: January 30, 2007Assignee: Surface Logix, Inc.Inventors: Evelyn Wang, Rocco Casagrande, Amar Kendale, Enoch Kim, Emanuele Ostuni, Olivier Schueller
-
Patent number: 7169578Abstract: The present invention provides methods and devices for screening a single cell or a small group of cells for a desired biological activity. In particular, the present invention provides for delivering cell(s) to a plurality of cell isolation regions of a cell isolation device, transferring the cell(s) to a plurality of wells of a cell expansion device and detecting the potential desired biological activity of the cell(s). Each of the cell isolation regions comprise a bioaffinity region capable of binding a single cell or a small group of cell(s). This binding of cell(s) may be accomplished through the use of bioaffinity ligands immobilized in the bioaffinity regions of the cell isolation regions. Preferably, the wells of the cell expansion device encompass a cavity that provides sufficient volume for cell proliferation.Type: GrantFiled: July 29, 2002Date of Patent: January 30, 2007Assignee: Surface Logix, Inc.Inventors: Evelyn Wang, Rocco Casagrande, Amar Kendale, Enoch Kim, Emanuele Ostuni, Olivier Schueller
-
Patent number: 7163819Abstract: Genes encoding bacterial oxygen binding proteins are provided. Recombinant expression of at least one of the present bacterial hemoglobin genes increased the growth characteristics and/or carotenoid production levels in microbial host cells grown under microaerobic conditions.Type: GrantFiled: April 4, 2006Date of Patent: January 16, 2007Assignee: E. I. du Pont de Nemours and CompanyInventors: Qiong Cheng, Michael P. Perry, Luan Tao
-
Patent number: 7157257Abstract: A method is described for treating biological cells and/or their cell components with electrical fields in a reaction medium, in which an inhibitor is added to the reaction medium to counteract the action of enzymes that break down protein.Type: GrantFiled: January 22, 2003Date of Patent: January 2, 2007Assignee: Eppendorf AGInventor: Ulrich Zimmermann
-
Patent number: 7148040Abstract: The present invention relates to genetically altered hybridomas, myelomas and B cells. The invention also relates to utilizing genetically altered hybridomas, myelomas and B cells in methods of making monoclonal antibodies. The present invention also provides populations of hybridomas and B cells that can be utilized to make a monoclonal antibody of interest.Type: GrantFiled: February 20, 2002Date of Patent: December 12, 2006Assignees: University of Georgia Research Foundation, Inc., Abeome CorporationInventors: Richard B. Meagher, Vince Laterza
-
Patent number: 7118889Abstract: The invention generally relates to compositions and methods for identifying and testing tyrosine kinase signaling pathway agonists and antagonists, and more particularly, methods and compositions for screening compounds and identifying compounds that will modulate the interaction of protein tyrosine kinase substrates with their intracellular ligands, as well as between their intracellular ligands and other members of the signaling pathway.Type: GrantFiled: June 19, 2000Date of Patent: October 10, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Lawrence E. Samelson, Weiguo Zhang
-
Patent number: 7109003Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.Type: GrantFiled: July 1, 2003Date of Patent: September 19, 2006Assignees: Abgenix, Inc., Pfizer Inc.Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
-
Patent number: 7109309Abstract: It is intended to provide an antibody specific to HbA1c, antibody-producing cells capable of supplying the antibody in a stable state in the future, and a method of constructing the antibody-producing cells without any probability factors, and a method which comprises fusing mouse spleen cells, which have been sensitized with an immunogen composed of a compound containing the following structural formula (I) and a binding protein, with a myeloma-origin cell line, obtaining monoclonal antibody-producing cells by cloning, and then purifying and acquiring the monoclonal antibody produced by these cells into the culture supernatantType: GrantFiled: July 13, 2001Date of Patent: September 19, 2006Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Nobuyuki Shigetoh, Hiroshi Nakayama, Keiko Yugawa, Fumihisa Kitawaki
-
Patent number: 7081348Abstract: There is provided an immunoassay by which the amount of human medullasin present inside granulocytes, which are one leukocyte component in blood, can be determined with high accuracy and with good reproducibility. Also provided is an immunoassay of medullasin, wherein when measuring the medullasin in blood using an anti-human medullasin antibody, the determination of the amount of human medullasin in a blood sample using said anti-human medullasin antibody is carried out after treating the blood sample with an aqueous liquid having a specific osmotic pressure different to the osmotic pressure of blood to completely break up the leukocytes. Also provided is a method of diagnosing multiple sclerosis characterized in that the human medullasin content of a blood sample is measured using an immunoassay, and the onset of multiple sclerosis and the extent of the disease is diagnosed according to the size of, or changes in, this measured value.Type: GrantFiled: June 29, 2004Date of Patent: July 25, 2006Assignee: Dainichiseika Color & Chemicals Mfg. Co., Ltd.Inventors: Hideaki Suzuki, Kiyoshi Takahashi, Hisashi Katsuragi, Yosuke Aoki
-
Patent number: 7067268Abstract: The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand. The immunoassay method using the monoclonal antibodies of the invention by the sandwich technique (in particular the sandwich technique using the monoclonal antibody and an antibody recognizing an intermediate portion of the 19P2 ligand) can assay the 19P2 ligand or a derivative thereof specifically and with high sensitivity.Type: GrantFiled: May 20, 1999Date of Patent: June 27, 2006Assignee: Takeda Chemical Industries, Ltd.Inventors: Hirokazu Matsumoto, Chieko Kitada, Shuji Hinuma
-
Patent number: 7060276Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.Type: GrantFiled: March 25, 2002Date of Patent: June 13, 2006Assignee: The United States of America as represented by the Secretary of the ArmyInventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P. V. Nair
-
Patent number: 7056702Abstract: The invention provides antibodies reactive with distinct lipocalin epitopes that are useful for detecting inflammation and bacterial infections in mammals.Type: GrantFiled: December 16, 2002Date of Patent: June 6, 2006Inventors: Julie M. Villanueva, Stephen Quirk
-
Patent number: 6919183Abstract: A method for identifying and isolating cells which produce secreted proteins. This method is based upon a specific characteristic or the expression level of the secreted protein by transiently capturing the secreted protein on the surface of an individual cell, allowing selection of rare cell clones from a heterogeneous population. Also provided is the use of this method to generate cells which produce a desired level of secreted protein or secreted protein of a particular characteristic(s), and organisms which possess such cells. In particular, the method allows rapid isolation of high expression recombinant antibody-producing cell lines, or may be applied directly to rapid isolation of specific hybridomas, or to the isolation of antibody-producing transgenic animals. This method is applicable for any cell which secretes protein.Type: GrantFiled: January 16, 2002Date of Patent: July 19, 2005Assignee: Regeneron Pharmaceuticals, Inc.Inventors: James P. Fandl, Neil Stahl, Gang Chen, George D. Yancopoulos
-
Patent number: 6863892Abstract: A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers. The 158P1D7 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.Type: GrantFiled: August 22, 2001Date of Patent: March 8, 2005Assignee: Agensys, Inc.Inventors: Mary Faris, Rene S. Hubert, Arthur B. Raitano, Daniel E. H. Afar, Elana Levin, Pia Challita-Eid, Aya Jakobovits
-
Patent number: 6846667Abstract: The present invention is based on the identification of a series of virulence genes in E. coli K1, the products of which may be implicated in the pathogenicity of the organisms. The identification of the genes allows them, or their expressed products, to be used in a number of ways to treat infection.Type: GrantFiled: November 9, 1999Date of Patent: January 25, 2005Assignee: Microscience, Ltd.Inventors: Helen Rachel Crooke, Enda Elizabeth Clarke, Paul Howard Everest, Gordon Dougan, David William Holden, Jacqueline Elizabeth Shea, Robert Graham Feldman
-
Patent number: 6844164Abstract: An antibody biding specifically to rat's acrosome reacted sperm is produced and hybridomas (FARS-91 and FARS-92 strains) capable of stably proliferating are obtained by fusing mouse spleen cells having a high antibody titer against rat's acrosome reacted sperm with mouse-origin myeloma cells and screening fused cells reacting strongly with rat's acrosome reacted sperm. From these hybridomas, monoclonal antibodies selectively binding to rat's acrosome reacted sperm can be obtained. Thus, a diagnostic method for evaluating fertility of rat's spermatozoa is presented.Type: GrantFiled: October 23, 2000Date of Patent: January 18, 2005Assignee: FUSO Pharmaceutical Industries, Ltd.Inventors: Yoshihiro Kuwahara, Michinori Hasegawa, Kiyotsugu Isaka, Hiromasa Araki
-
Patent number: 6767709Abstract: There is provided an immunoassay by which the amount of human medullasin present inside granulocytes, which are one leukocyte component in blood, can be determined with high accuracy and with good reproducibility. Also provided is an immunoassay of medullasin, wherein when measuring the medullasin in blood using an anti-human medullasin antibody, the determination of the amount of human medullasin in a blood sample using said anti-human medullasin antibody is carried out after treating the blood sample with an aqueous liquid having a specific osmotic pressure different to the osmotic pressure of blood to completely break up the leukocytes. Also provided is a method of diagnosing multiple sclerosis characterized in that the human medullasin content of a blood sample is measured using an immunoassay, and the onset of multiple sclerosis and the extent of the disease is diagnosed according to the size of, or changes in, this measured value.Type: GrantFiled: November 20, 2000Date of Patent: July 27, 2004Assignee: Dainichiseika Color & Chemicals Mfg. Co., Ltd.Inventors: Hideaki Suzuki, Kiyoshi Takahashi, Hisashi Katsuragi, Yosuke Aoki
-
Patent number: 6733997Abstract: A universal secretory signal originally derived from a piscine vitellogenin (Vtg) gene is inserted into various expression vectors for driving the secretion of the recombinant protein into the culture medium. This enhances the detection, quantification and downstream scaled-up purification of a recombinant protein of interest. The secretory signal system is very versatile, being conveniently and widely applicable to an array of heterologous host cells such as bacteria, yeast, insect, piscine, and mammalian cell lines (e.g., COS, CHO, NIH/3T3). The said secretory system is also applicable as a reporter vector for secretion of reporter proteins/enzymes, thus, enabling the detection of the reporter proteins (e.g., CAT, GFP) in the culture medium.Type: GrantFiled: October 26, 1999Date of Patent: May 11, 2004Assignee: National University of SingaporeInventors: Jeak Ling Ding, Nguan Soon Tan, Bow Ho, Toong Jin Lam
-
Patent number: 6709873Abstract: This invention relates to the production of polyclonal and monoclonal antibodies to specific sites of rapamycin (Sirolimus). The reactivity of these poly and monoclonal antibodies make them particularly useful for immunoassays for therapeutic drug monitoring (TDM). These immunoassays or TDM kits may include polyclonal or monoclonal antibodies to specific sites of rapamycin. These kits may also include various combinations of polyclonal antibodies, polyclonal and monoclonal antibodies or a panel of monoclonal antibodies. Rapamycin conjugate immunogens are prepared for the immunization of a host animal to produce antibodies directed against specific regions of the rapamycin molecule. By determining the specific binding region of particular antibody, immunoassays which are capable of distinguishing between the parent molecule, active metabolites, inactive metabolites and other structurally similar immunosuppressant compounds are developed.Type: GrantFiled: August 15, 2000Date of Patent: March 23, 2004Assignee: Isodiagnostika Inc.Inventors: Randall W. Yatscoff, Andrew J. Malcolm, Selvaraj Naicker